Week of February 21st 2022 | Vol. 11, Issue 8
Events Hosted or Attended by Bourne Partners
March 21-24, 2022 - New York City, NY
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
June 13-16, 2022 - San Diego, CA
October 2022 - Charlotte, NC
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
Insight Into Healthcare Related Industries
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
A Sampling of Industry Headlines From Last Week
February 15, 2022 - Fierce Biotech
All the biopharma world is talking about right now is M&A. Who’s going to buy? How much are they willing to spend? Who’s going to get bought?
Eli Lilly has jumped back into bed with ImmunoGen. Several years after terminating an earlier deal, Lilly has struck a new agreement, paying $13 million upfront and committing up to $1.7 billion in total to pick up rights to another antibody-drug conjugate (ADC) technology.
Equillium, with only one asset in its pipeline thanks to an in-licensing deal, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics.
Less than six months after it raised $125 million for its neuro-rehabilitation video game platform, MindMaze has scored another round of venture capital.

Life-changing treatments might take years to pass necessary regulatory approvals in certain countries, if at all. Tanner enables patient access to innovative medicines through EAPs. Learn more.

The availability of pharmaceuticals can be limited in certain emerging markets around the world. Learn more about how TannerLAC ensures products reach patients in Latin America in this Q&A with Carolina Cortez and Margarita Chala.